Newsroom
Product launches, research breakthroughs, and company milestones from the Vecentra team.
A widely used antifungal with unexpected anticancer activity and more than fifteen years of mechanistic debate. In a structural comparison against SMO and VDAC1, Vecentra favours SMO as the clearer predicted interaction, and turns a long question into a focused next experiment.
Read storyPotency does not separate the oncology drugs that reached patients from the ones that failed. Across 22 compounds and 8 cancer targets, target engagement and cohort biology do. A retrospective research note, with the limits stated plainly.
Read storyGnosis unifies molecular generation and multi-property evaluation (target engagement, selectivity, safety, omics, and ADMET) into a single decision system, with a growing focus on RNA-targeting and induced-proximity chemistry to reach historically undruggable targets.
Read storyThe most valuable signal in early cancer drug design is not raw potency, it is selectivity. A note on why predicting cytotoxicity well means predicting biology, and how multi-omics nudges models toward mechanism instead of memorisation.
Read storyAn early company note on who is building Gnosis, what the resources are for, and why we are not going to pretend a round announcement is the interesting part.
Read storyThe product is not an endpoint. It is a decision about which molecules to make next, delivered as a Candidate Intelligence Codex rather than an unattended API.
Read story